A United States Senator has disclosed a series of stock trades, some raising questions about possible insider information use ...

It is being billed by doctors as the best drug in weight management, compared to similar drugs available in the market ...

Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...

Obesity affects approximately 100 million Indian adults and is linked to over 200 health complications, including heart ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly shares climbed after launching its weight-loss drug, Mounjaro, in India at a steep discount. The drug is now ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.